Issue of Equity

5 August 2020

Physiomics plc

("Physiomics" or "the Company")

Issue of Equity

Physiomics plc, a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, announces that, further to its announcement earlier today and following the receipt of an additional notice of exercise of employee options, 90,000 ordinary shares of 0.4p each in the Company ("Ordinary Shares") (the "Options Shares") will be issued to the an employee at an exercise price of 3.16p per option.

Application will be made for the Option Shares to be admitted to trading on AIM, and dealings in the Option Shares are expected to commence on 11 August 2020 ("Admission"). Following Admission, the total number of Ordinary Shares in issue will increase to 97,334,778.

For the purposes of the Financial Services Authority's Disclosure Guidance and Transparency Rules (the "DTRs"), the issued ordinary share capital of the Company following Admission will consist of 97,334,778 Ordinary Shares with voting rights attached (one vote per Ordinary Share). There are no Ordinary Shares held in treasury. This total voting rights figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interests in, or a change to their interest in, Physiomics under the DTRs. The Company's share capital additionally comprises 2,481,657,918 deferred shares of 0.036p each which are not quoted and to which no voting rights attach.

Enquiries:

Physiomics plc

Dr Jim Millen, CEO

+44 (0)1865 784 980

Strand Hanson Ltd (NOMAD)

Richard Tulloch & James Dance

+44 (0)20 7409 3494

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341